Back

Acoramidis-mediated improvement in NT-proBNP at month 30 compared with placebo in patients with ATTR-CM: results from the ATTRibute-CM study

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Cardiac amyloidosis Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Nitasha Sarswat

University of Chicago Medical Center, Chicago (United States of America)

4 More presentations in this session

Presentation thumbnail
Pyrophosphate scintigram as a potential imaging index of therapeutic efficacy for transthyretin cardiac amyloidosis
Mr S. Saito (Shimotsuke, JP)
Abstract Slides Video
Presentation thumbnail
Two-year cardiac follow-up of transthyretin amyloid deposition in surgical specimens from carpal tunnel syndrome and rotator cuff tear cases
Assistant Professor T. Umemoto (Tokyo, JP)
Abstract Slides
Presentation thumbnail
Spatial transcriptomics of human cardiac biopsy samples reveals gene expression signature of cardiac amyloidosis
Mr S. Saito (Shimotsuke, JP)
Abstract Slides Video
Presentation thumbnail
Cardiac transthyretin amyloidosis in patients with conduction system disease
Doctor J. Pudich (Ostrava, CZ)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiac amyloidosis

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Acoramidis leads to clinically meaningful improvements from baseline in NT-proBNP and 6-minute walk distance in patients with transthyretin amyloid cardiomyopathy: observations from ATTRibute-CM
thumbnail
Congress Presentation
Acoramidis has a beneficial effect compared with placebo on change from baseline in NAC ATTR stage at month 30 in patients with ATTR-CM: results from the ATTRibute-CM study
thumbnail
Congress Session
Advances in amyloidosis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources